审计报告 苏州纳微科技股份有限公司 容诚审字[2025]200Z1703号 容诚会计师事务所(特殊普通合伙 ) 中国·北京 目 录 | 序号 | 内 | 容 | | 页码 | | --- | --- | --- | --- | --- | | 1 | 审计报告 | | 1-6 | | | 2 | 合并资产负债表 | | 1 | | | 3 | 合并利润表 | | 2 | | | 4 | 合并现金流量表 | | 3 | | | 5 | 合并所有者权益变动表 | | 4-5 | | | 6 | 母公司资产负债表 | | 6 | | | 7 | 母公司利润表 | | 7 | | | 8 | 母公司现金流量表 | | 8 | | | 9 | 母公司所有者权益变动表 | | 9-10 | | | 10 | 财务报表附注 | | 11 - | 132 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26（100037） TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn h ...

一、并购 1、纳微科技：投资1576.92万元取得纳信科技51.25%股权。 5、三联锻造：设立机器人及航空部件研究院分公司。 6、金杨股份：投资不超9000万美元建设马来西亚锂电池精密结构件项目。 7、中毅达：公司生产产能保持稳定，近期无新建计划。 二、回购、增持 1、古越龙山：拟2亿元-3亿元回购。 2、凯撒旅业：控股股东拟0.7亿元-1.1亿元增持。 三、对外投资，日常经营 1、星网宇达：公司与吉林省仿生机器人创新中心签署战略合作协议。 2、中国平安：计划发行不超过500亿元人民币的境内债券融资工具。 3、纽威数控：拟投资8.5亿元建设五期高端智能数控装备项目。 4、元利科技：拟投资7.6亿元建设年产25000吨受阻胺类光稳定剂项目。 1、恒玄科技：2024年净利润4.60亿，同比增长272% 拟每10股派发12元并转增4股。 四、业绩变动 2、中微公司：一季度净利润3.13亿元 同比增长25.67%；公司针对先进逻辑和存储器件制造中关键刻蚀 工艺的高端产品新增付运量显著提升，六种薄膜设备已顺利进入市场。 3、惠而浦：一季度净利润1.16亿元，同比增长1029%；主要系外销订单增加。 4、甘李药业：一季 ...

纳微科技公告，公司通过股权转让及增资方式，取得苏州纳信科技有限公司51.25%股权，投资总额 1576.92万元。交易完成后，纳信科技注册资本由2000万元增至3076.92万元。纳信科技主营溶剂回收膜 材料的研发、生产及销售。此次投资有助于公司为医药客户提供更全面的分离纯化整体解决方案，增强 公司在生物医药产业的竞争力和品牌影响力。 ...

导读： 关税战引发的"蝴蝶效应"正在重塑全球科学仪器产业格局，中国仪器企业站在技术攻坚与市场洗牌的十字路口。仪器信息网梳理了国产厂商针对关税战的 回应，并汇总了各品类仪器的国产替代工作进展。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 过去的两周时间内，特朗普政府的关税政策犹如一场全球经济的"压力测试"，以"美国优先"为名掀起的贸易博弈，搅动着国际供应链的稳定。 频繁的"朝令夕改"，到即将开始的"关税谈判"，全球经济的韧性正承受着前所未有的挑战，全球市场不稳定性的加剧使企业被迫在政策摇摆中 调整战略。 对于科学仪器行业来说，这场关税战引发的"蝴蝶效应" 正在重塑全球产业格局： 美国仪器品牌在这场关税风暴中面临着前所未有的冲击，被迫进行提价可能损失销量、不提价则需压缩成本的两难选择； 中国仪器企业则站在技术攻坚与市场洗牌的十字路口：在应对进口成本激增、技术 "卡脖子" 等短期阵痛的同时，迎来了国产替代加速、市场 格局重构的战略机遇。 关税战将对国产仪器产生怎样的影响？ 在美国出口管制与关税不断加码的背景下，国产科学仪器面临供应链、 ...

国泰海通主要观点如下： 政策受益，科研制药上游是战略新兴产业自主可控的重要组成部分 智通财经获悉，国泰海通发布研报称，科研制药上游作为战略新兴产业自主可控的重要组成部分，正迎 来政策与市场的双重驱动。国家层面持续出台支持政策，包括《"十四五"生物经济发展规划》要求提升 产业链安全水平，科技部明确"高端产品研发自主化"目标，叠加进口品牌受关税成本上升影响，具备自 主创新能力的国产企业迎来替代窗口期。重点推荐泰坦科技(688133.SH)、阿拉丁(688179.SH)、纳微科 技(688690.SH)等核心标的。 风险提示：关税地缘政治风险、全球医药研发景气度风险、创新药鼓励扶持政策不达预期风险。 中国市场正以庞大的人口基数与快速增长的生物医药需求逐渐成为生命科学产业的新兴市场，未来几年 中国生命科学制品市场规模将快速增长，生命科学制品的高端市场长期由欧美企业主导，该行认为，国 产替代空间依然巨大。在国产替代的大趋势下，具备自主创新研发能力、能够提供性能与进口产品相 似、甚至优于进口产品的企业将在激烈的市场竞争中脱颖而出。 若进口品牌受关税影响成本上升，国产品牌性价比有望进一步凸显 根据默克、珀金埃尔默等进口品牌 ...

Group 1 - The core viewpoint is that the upstream pharmaceutical research and development sector is a crucial part of the strategic emerging industry, benefiting from both policy and market drivers [1][2] - The Chinese government has introduced a series of supportive policies for the biopharmaceutical industry, emphasizing the need for domestic substitution and enhancing the safety and stability of the supply chain [2][3] - The report highlights key recommended stocks such as Titan Technology (688133.SH), Aladdin (688179.SH), and Nawei Technology (688690.SH) as core targets for investment [1] Group 2 - The domestic innovation-driven substitution is expected to rapidly increase the domestic substitution rate in the biopharmaceutical market, which is becoming a new emerging market due to its large population and growing demand [3] - The high-end market for life science products has been dominated by European and American companies, but there is significant potential for domestic alternatives to emerge [3] - The cost pressure on imported brands due to tariffs is expected to create a favorable environment for domestic brands, enhancing their competitiveness [4]

Investment Rating - The report assigns an "Overweight" rating for the industry [2][10]. Core Insights - The upstream research and development pharmaceutical sector is a crucial part of China's key industrial chain, with a focus on domestic substitution accelerated by the impact of U.S. tariff events [4]. - The biopharmaceutical industry is recognized as a strategic emerging industry, with various supportive policies from the government aimed at increasing the domestic supply rate of high-end products [5]. - The domestic innovation-driven substitution is expected to enhance the domestic substitution rate rapidly, as the Chinese market is becoming a new emerging market for life science products due to its large population and growing demand [5]. - The cost pressure on imported brands due to tariffs is likely to highlight the cost-effectiveness of domestic brands, creating a favorable environment for domestic companies like Titan Technology, Aladdin, and Nanwei Technology [5]. Summary by Sections - **Policy Benefits**: The biopharmaceutical industry is classified as a strategic emerging industry, with government policies promoting domestic substitution and innovation [5]. - **Market Growth**: The life science products market in China is projected to grow rapidly, with significant opportunities for domestic companies to replace imported products [5]. - **Competitive Advantage**: Companies with strong R&D capabilities that can match or exceed the performance of imported products are expected to thrive in the competitive landscape [5].

Core Viewpoint - The lawsuit involving Suzhou Nawei Technology Co., Ltd. is currently in the appeal stage, with both the plaintiff and defendants contesting the first-instance judgment. The company is a third party in the case and does not bear any liability, ensuring that its operations and profits remain unaffected by the litigation [2][11]. Summary by Sections Lawsuit Background - On December 5, 2022, the company received a civil complaint from Han Han, who is seeking to confirm a claim of 51,556,500 yuan for a share of 5,698,350 yuan held by Suzhou Nabai [3]. - The lawsuit has evolved, with Han Han modifying his claims on August 31, 2023, to seek 38,273,600 yuan for a share of 4,230,240 yuan and additional compensation for 2,656,580 shares [4]. - By May 31, 2024, Han Han introduced an alternative claim for 302,596,775.52 yuan in damages, along with interest calculations based on LPR standards [5]. Court Decisions and Appeals - On August 12, 2024, the court ruled that Suzhou Nabai must pay Han Han 18,994,500 yuan, while other claims were dismissed [6]. - In September 2024, both parties filed appeals against the judgment, with Suzhou Nabai seeking to overturn the ruling and Han Han requesting full support for his claims [6][8]. Recent Developments - To mitigate the impact of the lawsuit on the company's stock incentive plans, Suzhou Nabai and its chairman, Dr. Jiang Biwang, submitted a request to the Jiangsu Provincial High Court to replace frozen assets with equivalent shares [9]. - The court has since ruled to freeze 5,112,900 shares held by Dr. Jiang while lifting the asset preservation measures on Suzhou Nabai's partnership interests [9][10]. Impact on Company Operations - The company maintains that the lawsuit will not affect its operational stability or governance, as it is involved as a third party and is not liable for any claims [11]. - The freezing of 1.27% of the company's shares held by Dr. Jiang will not alter the control structure of the company, ensuring that its management remains stable [11].

证券代码：688690 证券简称：纳微科技 公告编号：2025-005 苏州纳微科技股份有限公司 关于涉及诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、2022 年 12 月 5 日，公司收到苏州市中级人民法院送达的关于韩寒起诉公 司、苏州纳百及公司董事长江必旺博士等三方的《民事起诉书》等相关材料。韩 案件所处的诉讼阶段：原告、被告就一审判决分别提起上诉 原告：韩寒 寒起诉要求（1）确认以 51,556,500 元的对价享有苏州纳百持有苏州纳研的财产 份额 5,698,350 元；（2）要求公司向韩寒支付针对 2,656,580 股激励股份的收购 价款 122,909,330.28 元，并承担资金占用损失。 具 体 内 容 详 见 公 司 于 2022 年 12 月 7 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《苏州纳微科技股份有限公司关于涉及诉讼的公告》 （公告编号：2022-100）。 被告一：苏州纳百管理咨询有限公司（以下简称"苏州纳百" ...

Group 1: Technology Innovation as a Core Support - The core argument is that technological innovation is a key variable and a hard support for China's economy to withstand external shocks, especially in the context of ongoing trade tensions with the U.S. [2] - China has been actively opening more R&D parks and promoting AI-driven innovation, showcasing a strong commitment to technological advancement despite external pressures [2][3]. Group 2: Case Studies of Technological Breakthroughs - Huagong Technology has transformed its previously constrained capabilities into a competitive advantage by developing advanced laser cutting technology, achieving the fastest welding speed in the automotive industry at 43 seconds per vehicle [3]. - The company has seen over 60% growth in overseas sales of its laser equipment, achieving full coverage in the European market [3]. - Nanwei Technology has disrupted the market with its nano-microspheres, leading to a 90% price drop in competing foreign products upon its launch [5][6]. Group 3: Policy Support and Ecosystem Development - The Suzhou Industrial Park has played a crucial role in fostering nanotechnology, becoming one of the world's major nanotechnology hubs through strategic investments and policy support [6][7]. - A series of coordinated policies at both central and local levels have been implemented to enhance technological innovation and industrial integration, positioning China to better navigate external challenges [7][8]. Group 4: Emerging Industries and Talent Development - The integration of education and technology is being accelerated, with initiatives like the "Academician Class" at Shenzhen University aimed at fostering early involvement of students in cutting-edge research [10]. - The Yangtze River Delta region is transforming its industrial landscape through collaborative efforts, focusing on high-tech sectors such as biomedicine and new energy vehicles [10][11]. Group 5: Quantum Technology and Future Prospects - GuoDun Quantum Technology is leveraging research from the University of Science and Technology of China to advance quantum computing, aiming to establish a robust quantum technology ecosystem [11]. - The market potential for new technologies and industries in China is significant, with experts suggesting that external pressures may accelerate the shift towards higher-end industrial chains [11].